R
Robert C. Gallo
Researcher at University of Maryland, Baltimore
Publications - 829
Citations - 69136
Robert C. Gallo is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Virus & Antibody. The author has an hindex of 145, co-authored 825 publications receiving 68212 citations. Previous affiliations of Robert C. Gallo include Global Virus Network & University of Maryland, Baltimore County.
Papers
More filters
Journal ArticleDOI
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
Hiroaki Mitsuya,Kent J. Weinhold,P A Furman,M H St Clair,S N Lehrman,Robert C. Gallo,Dani P. Bolognesi,David Walter Barry,Samuel Broder +8 more
TL;DR: The antiviral effects of a thymidine analogue,3'-azido-3'-deoxythymidine (BW A509U), which, as a triphosphate, inhibits the reverse transcriptase of HTLV-III/LAV, and the in vitro immune functions of normal T cells remain basically intact.
Journal ArticleDOI
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.
Barbara Ensoli,Luigi Buonaguro,Giovanni Barillari,Valeria Fiorelli,R Gendelman,Richard A. Morgan,Paul T. Wingfield,Robert C. Gallo +7 more
TL;DR: The data suggest that Tat can be released by a mechanism(s) other than cell death and that the cell growth-promoting activity and the virus-transactivating effect of extracellular Tat are mediated by different pathways.
Journal ArticleDOI
Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia.
TL;DR: Analysis of the proteins and nucleic acids of this retrovirus isolate indicates that it is closely related to HTLVCR, a retrov virus recently isolated and characterized from a patient with cutaneous T-cell lymphoma (mycosis fungoides) but distinct from known animal retroviruses.
Journal ArticleDOI
Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization
TL;DR: It is demonstrated that HTLV-III expression in lymph node and peripheral blood is very low in vivo and the lymph node hyperplasia observed in HT LV-III-associated lymphadenopathy is not directly due to proliferation of HTLV -III-infected lymphocytes.
Journal ArticleDOI
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
James R. Rusche,Kashi Javaherian,Charlene McDanal,J Petro,Debra Lynn,R Grimaila,A. J. Langlois,Robert C. Gallo,L O Arthur,Peter J. Fischinger +9 more
TL;DR: The principal epitope that elicits fusion-inhibiting antibodies is located in the central portion of gp120, and a 24-amino acid peptide (RP135, amino acids 307-330) completely blocks fusion inhibition activity of both antisera and the activity of serum from a chimpanzee infected with HTLV-IIIB.